Open Medicine
(Mar 2018)
Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China
- Chen Yu,
- Ye Peng,
- Ren Chongwu,
- Ren Pengfei,
- Ma Zheng,
- Zhang Lin,
- Zhou Wenliang,
- Jiang Changjie
Affiliations
- Chen Yu
- The Sixth People‘s Hospital of Zhengzhou, Zheng zhou, China
- Ye Peng
- Hebi Infectious Disease Hospital, Hebi, China
- Ren Chongwu
- Zhoukou Infectious Disease Hospital, Zhoukou, China
- Ren Pengfei
- The Sixth People‘s Hospital of Zhengzhou, Zheng zhou, China
- Ma Zheng
- The Sixth People‘s Hospital of Zhengzhou, Zheng zhou, China
- Zhang Lin
- Hebi Infectious Disease Hospital, Hebi, China
- Zhou Wenliang
- Zhoukou Infectious Disease Hospital, Zhoukou, China
- Jiang Changjie
- Zhoukou Infectious Disease Hospital, Zhoukou, China
- DOI
-
https://doi.org/10.1515/med-2018-0010
- Journal volume & issue
-
Vol. 13,
no. 1
pp.
53
– 63
Abstract
Read online
To evaluate the pharmacoeconomics of three therapeutic schemes in treating anti-tuberluosis therapy -induced liver injury (anti-TB DILI).
Keywords
WeChat QR code
